Evaluation of the Direct Flow Medical Percutaneous Aortic Valve 18F System for the Treatment of Patients With Severe Aortic Stenosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2012 by Direct Flow Medical, Inc..
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Direct Flow Medical, Inc.
ClinicalTrials.gov Identifier:
NCT01475799
First received: November 17, 2011
Last updated: June 18, 2012
Last verified: June 2012
  Purpose

The purpose of the study is to determine the safety and performance of the Direct Flow Medical study valve and delivery procedure.


Condition Intervention
Aortic Valve Stenosis
Procedure: replacement of the aortic stenotic valve

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Evaluation of the Direct Flow Medical Percutaneous Aortic Valve 18F System for the Treatment of Patients With Severe Aortic Stenosis

Resource links provided by NLM:


Further study details as provided by Direct Flow Medical, Inc.:

  Eligibility

Ages Eligible for Study:   70 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Severe aortic valve stenosis determined by echocardiogram and Doppler, defined as: mean gradient >40 mmHg or peak jet velocity >4.0 m/s and an aortic valve area ≤0.8 cm2 or aortic valve area index ≤0.5 cm2/m2
  2. Symptomatic aortic valve stenosis demonstrated by angina, congestive heart failure, NYHA Functional Class ≥ II, or syncope
  3. Patient is an extreme risk candidate for open surgical aortic valve repair such that the site Investigators (interventional cardiologist and cardiothoracic surgeon) agree that medical factors preclude operation, based on the conclusion that the probability of death or serious morbidity exceeds the probability of meaningful improvement due to the patient's co-morbidities (such as, but not limited to, severe COPD, porcelain aorta, previous thorax irradiation) or logistic EuroSCORE ≥ 20
  4. ≥ 70 years old
  5. Patient has been informed of the nature of the study and has provided written informed consent
  6. Patient and treating physician agree that the patient will return for all required post-procedure follow-up visits

Exclusion Criteria:

  1. Patient is a surgical candidate for aortic valve replacement
  2. Congenital bicuspid or unicuspid valve determined by echocardiography
  3. Native valve annulus diameter is <19mm or >26mm determined by the screening CT scan
  4. Extreme asymmetrical calcification of the native aortic valve determined by the screening CT scan
  5. Native valvular or peripheral vascular anatomy is not appropriate for the DFM bioprosthesis and 18F delivery system
  6. Left ventricular ejection fraction (LVEF) <30% determined by resting echocardiogram
  7. Evidence of an acute myocardial infarction (Refer to Definitions in Section 8) within 30 days prior to the study procedure
  8. Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the study procedure
  9. Any planned surgical or percutaneous coronary or peripheral procedure to be performed during the study procedure or prior to 30 day follow-up visit
  10. Need for emergency surgery for any reason
  11. Untreated clinically significant ( > 70% obstruction) coronary artery disease requiring revascularization
  12. Prior aortic or mitral valve surgery
  13. Pre-existing prosthetic heart valve in any position
  14. Mitral insufficiency greater than moderate determined by resting echocardiography
  15. Echocardiographic evidence of intra-cardiac mass, thrombus or vegetation
  16. Thoracic aortic aneurysm (TAA)
  17. Abdominal aortic aneurysm (AAA) >4.5 cm
  18. Presence of an endovascular stent graft for treatment of AAA or TAA
  19. Hypertrophic cardiomyopathy
  20. Hemodynamic instability (e.g. requiring inotropic support)
  21. Trans-esophageal echocardiography (TEE) is contraindicated
  22. Renal insufficiency (creatinine > 3.0 mg/dL) and/or end-stage renal disease requiring dialysis at the time of screening
  23. Active endocarditis or sepsis within 6 months prior to the study procedure
  24. Stroke or transient ischemic attack (TIA) within 6 months prior to the study procedure
  25. Cardiogenic shock within 30 days prior to the study procedure
  26. Active peptic ulcer or upper GI bleeding within 3 months prior to the study procedure
  27. Leukopenia (WBC <3000/mm³), acute anemia (Hb <9 g/dL), or thrombocytopenia (platelet count <100,000 cells/mm3)
  28. History of bleeding diathesis or coagulopathy or refusal of blood transfusions
  29. A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel, or sensitivity to contrast media, which cannot be adequately pre-medicated
  30. Currently participating in an investigational drug or another device trial
  31. Previously enrolled in this study
  32. Patient refusal of surgery
  33. Life expectancy thought to be <12 months
  34. Dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01475799

Contacts
Contact: Brian Sheahan (707) 576-0420

Locations
France
Recruiting
Massy, France
Recruiting
Toulouse, France
Germany
Recruiting
Hamburg, Germany
Italy
Recruiting
Milan, Italy
United Kingdom
Recruiting
London, United Kingdom
Sponsors and Collaborators
Direct Flow Medical, Inc.
  More Information

No publications provided

Responsible Party: Direct Flow Medical, Inc.
ClinicalTrials.gov Identifier: NCT01475799     History of Changes
Other Study ID Numbers: IP 010
Study First Received: November 17, 2011
Last Updated: June 18, 2012
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Constriction, Pathologic
Aortic Valve Stenosis
Pathological Conditions, Anatomical
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction

ClinicalTrials.gov processed this record on September 22, 2014